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Abstract
Emerging genetic therapies for rare disorders at high cost, cannot realistically address the global burden of disease.
Stakeholders must develop new pathways to ensure safe, fair and sustainable provision of such therapies.
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Emerging genetic therapies for rare
disorders
A disease or disorder is defined as rare in Europe when it
affects fewer than 1 in 2000 peopleand based on the Food
and drug admistration (FDA) definition from the US, when
it affects less than 200,000 at any one time. Genetic factors
contribute to the etiology in 80% of those with rare dis-
eases, and other contributing factors, including infection,
account for the remaining the cases. The recent emergence
of gene technologies has led to the development of ther-
apies to treat some of the once incurable diseases. Cur-
rently, there are more than 230 gene therapy efforts such
as splicing modifiers, exon skipping protocols, monoclonal
antibodies, and several ‘molecular plaster’ studies. Increas-
ing numbers of these therapies are being demonstrated to
show benefit and are being approved by health care author-
ities leading to availability in the market [1][2][3][4].
However, although these discoveries have provided the
real possibility of treatment and cure to previously con-
sidered untreatable and often life-limiting diseases, at this
point several concerns have arisen including primarily the
high cost, access to the intervention and the potential risks
[5]. These are mainly based on the following independent
factors. First, clinical studies are conducted on a narrowly
defined group with a minimal number of cases (usually less
than 200), but the therapy is expected to be applied to a
more diverse population. For example, a molecule has been
approved by the FDA in all types of a given rare genetic dis-
order, however the original study was only conducted in ba-
bies less than 6 months of age [1][6]. Secondly at this time
the adverse effects portfolio in relation to these treatments
is still accumulating, adequate data may not be available on
chronic and late stage forms of disease, and uncertainities
exist regarding long term benefits [2][3][4]. The third is-
sue is related to cost regulation. These drugs are extremely
expensive costing up to several million dollars which places
governmental bodies and health care providers in a diffi-
cult position financially based upon the cumulative cost of
several hundred re-imbursements every year causing a true
burden on the health economy globally [5][7]. Last but not
least is the issue of the expectations of families which may
not match with the study end points. In other words, ‘End
point goals’ of patients and families in terms of clinically
relevant outcomes and improvements in quality of life may













































































Since the 1980s there have been enormous developments
in the whole gene therapy field which has led to significant
expectations in the community. For the time being, these
innovative therapies act as disease modifying procedures at
often prohibitive costs. But even if they fall short of mit-
igating all functional limitations in patients or eliminating
morbidities and not fulfilling in total the families’ expecta-
tions, those involved in the care of affected children con-
tinue to think positively. More effective treatments may be
here sooner than expected, although we are still years away
from definitive treatments. The cost of these interventions
will become an increasing obstacle not only for resource
poor settings but also for resource-rich regions if the cur-
rent trend is maintained. Going forward there needs to be
careful consideration of the cost benefit ratio of these inter-
ventions given the limited amount of resources available to
provide healthcare to the entire population.
The position statement of the ICNA proposes that coun-
terparts, regulators, decision makers and other party stake-
holders should work in unity to address this serious global
health matter for vulnerable children and families. Charac-
terizing these perspectives can help support decisions. High
cost is a potential barrier to accessing treatment worldwide
negating the possibility for impact for the majority of those
afflicted.
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